AUR-AE5G-TTM1-A-1-1-R-A742-41
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.570
- MYC_TARGETS_V2+0.500
- G2M_CHECKPOINT+0.460
- MYC_TARGETS_V1+0.450
- DNA_REPAIR+0.420
- ESTROGEN_RESPONSE_EARLY+0.370
- ESTROGEN_RESPONSE_LATE+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.330
- OXIDATIVE_PHOSPHORYLATION+0.320
- MTORC1_SIGNALING+0.280
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- IL6_JAK_STAT3_SIGNALING-0.490
- INFLAMMATORY_RESPONSE-0.440
- TNFA_SIGNALING_VIA_NFKB-0.420
- KRAS_SIGNALING_UP-0.410
- ANGIOGENESIS-0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- INTERFERON_GAMMA_RESPONSE-0.350
- COMPLEMENT-0.340
- IL2_STAT5_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.917 |
| 2 | TCGA-BH-A1FJ-01A-11R-A13Q-07 | — | B | 0.913 |
| 3 | TCGA-B6-A0WV-01A-11R-A109-07 | — | B | 0.909 |
| 4 | BSR_04_0040_A3_S71 | — | B | 0.907 |
| 5 | TCGA-AR-A0TY-01A-12R-A115-07 | — | B | 0.904 |
| 6 | TCGA-S3-A6ZH-01A-22R-A32P-07 | — | B | 0.900 |
| 7 | TCGA-B6-A0X5-01A-21R-A109-07 | — | B | 0.898 |
| 8 | TCGA-EW-A6SA-01A-21R-A32P-07 | — | B | 0.896 |
| 9 | BSR_15_0056_E1_S102 | — | B | 0.896 |
| 10 | MBCproject_0227_T2_RNA | — | B | 0.894 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.420 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.370 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.360 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| PEROXISOME | 0.140 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.050 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.030 | Inavolisib | — uncovered |